214 related articles for article (PubMed ID: 1362704)
1. A-77636: a potent and selective dopamine D1 receptor agonist with antiparkinsonian activity in marmosets.
Kebabian JW; Britton DR; DeNinno MP; Perner R; Smith L; Jenner P; Schoenleber R; Williams M
Eur J Pharmacol; 1992 Dec; 229(2-3):203-9. PubMed ID: 1362704
[TBL] [Abstract][Full Text] [Related]
2. A68930: a potent agonist selective for the dopamine D1 receptor.
DeNinno MP; Schoenleber R; MacKenzie R; Britton DR; Asin KE; Briggs C; Trugman JM; Ackerman M; Artman L; Bednarz L
Eur J Pharmacol; 1991 Jun; 199(2):209-19. PubMed ID: 1683288
[TBL] [Abstract][Full Text] [Related]
3. Differential anti-parkinsonian effects of benzazepine D1 dopamine agonists with varying efficacies in the MPTP-treated common marmoset.
Gnanalingham KK; Erol DD; Hunter AJ; Smith LA; Jenner P; Marsden CD
Psychopharmacology (Berl); 1995 Feb; 117(3):275-86. PubMed ID: 7770603
[TBL] [Abstract][Full Text] [Related]
4. ABT-431: the diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease.
Shiosaki K; Jenner P; Asin KE; Britton DR; Lin CW; Michaelides M; Smith L; Bianchi B; Didomenico S; Hodges L; Hong Y; Mahan L; Mikusa J; Miller T; Nikkel A; Stashko M; Witte D; Williams M
J Pharmacol Exp Ther; 1996 Jan; 276(1):150-60. PubMed ID: 8558425
[TBL] [Abstract][Full Text] [Related]
5. Actions of the D1 agonists A-77636 and A-86929 on locomotion and dyskinesia in MPTP-treated L-dopa-primed common marmosets.
Pearce RK; Jackson M; Britton DR; Shiosaki K; Jenner P; Marsden CD
Psychopharmacology (Berl); 1999 Feb; 142(1):51-60. PubMed ID: 10102782
[TBL] [Abstract][Full Text] [Related]
6. Enhanced oral activity response to A77636 in neonatal 6-hydroxydopamine-lesioned rats.
Huang NY; Kostrzewa RM
Eur J Pharmacol; 1994 Feb; 253(1-2):163-6. PubMed ID: 7912196
[TBL] [Abstract][Full Text] [Related]
7. Selective dopamine antagonist pretreatment on the antiparkinsonian effects of benzazepine D1 dopamine agonists in rodent and primate models of Parkinson's disease--the differential effects of D1 dopamine antagonists in the primate.
Gnanalingham KK; Hunter AJ; Jenner P; Marsden CD
Psychopharmacology (Berl); 1995 Feb; 117(4):403-12. PubMed ID: 7604140
[TBL] [Abstract][Full Text] [Related]
8. The effects of D1 and D2 dopamine receptor agonist and antagonist on parkinsonism in chronic MPTP-treated monkeys.
Nomoto M; Fukuda T
Adv Neurol; 1993; 60():119-22. PubMed ID: 8093574
[No Abstract] [Full Text] [Related]
9. Dopamine D1 and D2 receptor interactions in the MPTP-treated marmoset.
Elliott PJ; Walsh DM; Close SP
Neurosci Lett; 1992 Aug; 142(1):1-4. PubMed ID: 1357609
[TBL] [Abstract][Full Text] [Related]
10. Endogenous dopaminergic tone and dopamine agonist action.
Treseder SA; Smith LA; Jenner P
Mov Disord; 2000 Sep; 15(5):804-12. PubMed ID: 11009183
[TBL] [Abstract][Full Text] [Related]
11. Dopamine supersensitivity and D1/D2 synergism are unrelated to changes in striatal receptor density.
LaHoste GJ; Marshall JF
Synapse; 1992 Sep; 12(1):14-26. PubMed ID: 1357762
[TBL] [Abstract][Full Text] [Related]
12. The actions of a D-1 agonist in MPTP treated primates show dependence on both D-1 and D-2 receptor function and tolerance on repeated administration.
Smith LA; Jackson MJ; Al-Barghouthy G; Jenner P
J Neural Transm (Vienna); 2002 Feb; 109(2):123-40. PubMed ID: 12075853
[TBL] [Abstract][Full Text] [Related]
13. 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding.
Breese GR; Duncan GE; Napier TC; Bondy SC; Iorio LC; Mueller RA
J Pharmacol Exp Ther; 1987 Jan; 240(1):167-76. PubMed ID: 3100767
[TBL] [Abstract][Full Text] [Related]
14. The dopamine D2 agonist LY 141865, but not the D1 agonist SKF 38393, reverses parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset.
Nomoto M; Jenner P; Marsden CD
Neurosci Lett; 1985 Jun; 57(1):37-41. PubMed ID: 3162113
[TBL] [Abstract][Full Text] [Related]
15. Relative potency and efficacy of some dopamine agonists with varying selectivities for D1 and D2 receptors in MPTP-induced hemiparkinsonian monkeys.
Domino EF; Sheng J
J Pharmacol Exp Ther; 1993 Jun; 265(3):1387-91. PubMed ID: 8099621
[TBL] [Abstract][Full Text] [Related]
16. Dopamine D1 receptor desensitization profile in MPTP-lesioned primates.
Blanchet PJ; Grondin R; Bédard PJ; Shiosaki K; Britton DR
Eur J Pharmacol; 1996 Aug; 309(1):13-20. PubMed ID: 8864687
[TBL] [Abstract][Full Text] [Related]
17. Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys.
Grondin R; Bédard PJ; Britton DR; Shiosaki K
Neurology; 1997 Aug; 49(2):421-6. PubMed ID: 9270571
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the D1-dopamine agonists SKF-38393 and A-68930 in neonatal 6-hydroxydopamine-lesioned rats: behavioral effects and induction of c-fos-like immunoreactivity.
Johnson KB; Criswell HE; Jensen KF; Simson PE; Mueller RA; Breese GR
J Pharmacol Exp Ther; 1992 Aug; 262(2):855-65. PubMed ID: 1354257
[TBL] [Abstract][Full Text] [Related]
19. Effect of D1 receptor stimulation in normal and MPTP monkeys.
Bédard PJ; Boucher R
Neurosci Lett; 1989 Sep; 104(1-2):223-8. PubMed ID: 2573015
[TBL] [Abstract][Full Text] [Related]
20. The differential behavioural effects of benzazepine D1 dopamine agonists with varying efficacies, co-administered with quinpirole in primate and rodent models of Parkinson's disease.
Gnanalingham KK; Hunter AJ; Jenner P; Marsden CD
Psychopharmacology (Berl); 1995 Feb; 117(3):287-97. PubMed ID: 7770604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
